Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors

Gossing, Wilhelm; Frohme, Marcus; Radke, Lars

doi:10.3390/biomedicines8060148

Cited by 8 publications

(3 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with miRNAs, there are fewer studies on lncRNAs in PitNETs. Some lncRNAs appear consistently up-or downregulated in tumor samples versus normal pituitary tissue [137]; however, circulating levels have not been sufficiently investigated in PitNETs so far.…”

Section: Non-invasive Biomarkers-circulating Non-coding Rnasmentioning

confidence: 99%

Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy

Tapoi,

Popa,

Tanase

et al. 2023

Cancers

View full text Add to dashboard Cite

Adenohypophysal pituitary tumors account for 10–15% of all intracranial tumors, and 25–55% display signs of invasiveness. Nevertheless, oncology still relies on histopathological examination to establish the diagnosis. Considering that the classification of pituitary tumors has changed significantly in recent years, we discuss the definition of aggressive and invasive tumors and the latest molecular criteria used for classifying these entities. The pituitary tumor microenvironment (TME) is essential for neoplastic development and progression. This review aims to reveal the impact of TME characteristics on stratifying these tumors in view of finding appropriate therapeutic approaches. The role of the pituitary tumor microenvironment and its main components, non-tumoral cells and soluble factors, has been addressed. The variable display of different immune cell types, tumor-associated fibroblasts, and folliculostellate cells is discussed in relation to tumor development and aggressiveness. The molecules secreted by both tumoral and non-tumoral cells, such as VEGF, FGF, EGF, IL6, TNFα, and immune checkpoint molecules, contribute to the crosstalk between the tumor and its microenvironment. They could be considered potential biomarkers for diagnosis and the invasiveness of these tumors, together with emerging non-coding RNA molecules. Therefore, assessing this complex network associated with pituitary neuroendocrine tumors could bring a new era in diagnosing and treating this pathology.

show abstract

Section: Non-invasive Biomarkers-circulating Non-coding Rnasmentioning

confidence: 99%

Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy

Tapoi,

Popa,

Tanase

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Although this may prove to be an important tool in the future, clinical utility is currently limited by our incomplete understanding of the complex pathogenesis of pituitary tumours and non-specificity of available biomarkers. 85 factors which influence the pathogenesis of pituitary tumours, their growth and degree of invasion. Future research requires larger, prospective, multicentre studies to help overcome the obstacle of the relative rarity of many pituitary tumour subtypes and to help characterize the role of these factors individually and interactively.…”

Section: G Enomi C and Epi G Ene Ti C In S I G Hts Into Pitu Itary Tumouri G Ene S Ismentioning

confidence: 99%

Towards precision medicine for clinically non‐functioning pituitary tumours

Lenders

Inder

McCormack

2021

Clinical Endocrinology

View full text Add to dashboard Cite

Objective: Clinically non-functioning pituitary tumours (NFPT) are a heterogenous group of neoplasms with diverse outcomes. The purpose of this narrative review was to summarize available data on predictive factors, both in routine practice and research settings.Design: A literature review was conducted for papers published in peer-reviewed journals, investigating clinical, radiological, pathological and genetic predictive factors in NFPT.Results: Several clinical and radiological factors have been associated with NFPT recurrence and/or aggressiveness, including larger size and pre-/post-operative growth rates. Application of transcription factor immunohistochemistry has given rise to improved subtype identification, including 'higher-risk' subtypes, in routine clinical practice. Numerous other pathological and genetic biomarkers have demonstrated promise for prognostication in the research setting. Conclusion:NFPT are a heterogenous group of tumours, characterized by diverse presentation, pathogenesis and outcomes. Ongoing refinements in understanding of tumour biology are likely to pave the way to improved integrative prognostication and precision medicine for NFPT.

show abstract

“…In recent years, increasing attention has been focused on identifying distinctive expression patterns of miRNAs in human biological fluids in order to use these molecules as novel diagnostic and prognostic biomarkers for various pathological conditions, including PAs [ 5 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs as Potential Biomarkers in Pituitary Adenomas

Donati

Aurilia

Palmini

et al. 2021

ncRNA

View full text Add to dashboard Cite

Pituitary adenomas (PAs) are one of the most common lesions of intracranial neoplasms, occurring in approximately 15% of the general population. They are typically benign, although some adenomas show aggressive behavior, exhibiting rapid growth, drug resistance, and invasion of surrounding tissues. Despite ongoing improvements in diagnostic and therapeutic strategies, late first diagnosis is common, and patients with PAs are prone to relapse. Therefore, earlier diagnosis and prevention of recurrence are of importance to improve patient care. MicroRNAs (miRNAs) are short non-coding single stranded RNAs that regulate gene expression at the post-transcriptional level. An increasing number of studies indicate that a deregulation of their expression patterns is related with pituitary tumorigenesis, suggesting that these small molecules could play a critical role in contributing to tumorigenesis and the onset of these tumors by acting either as oncosuppressors or as oncogenes, depending on the biological context. This paper provides an overview of miRNAs involved in PA tumorigenesis, which might serve as novel potential diagnostic and prognostic non-invasive biomarkers, and for the future development of miRNA-based therapeutic strategies for PAs.

show abstract

Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors

Cited by 8 publications

References 138 publications

Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy

Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy

Towards precision medicine for clinically non‐functioning pituitary tumours

MicroRNAs as Potential Biomarkers in Pituitary Adenomas

Contact Info

Product

Resources

About